Direxion Daily S&P Biotech Bull 3X ETF
LABU
27 hedge funds and large institutions have $41.1M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
17% more funds holding
Funds holding: 23 → 27 (+4)
0.02% less ownership
Funds ownership: 0.34% → 0.32% (-0.02%)
8% less call options, than puts
Call options by funds: $52.6M | Put options by funds: $57.2M
12% less capital invested
Capital invested by funds: $46.8M → $41.1M (-$5.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.56M |
| 2 |
Jane Street
New York
|
+$1.55M |
| 3 |
VF
Virtu Financial
New York
|
+$1.49M |
| 4 |
Citigroup
New York
|
+$1.36M |
| 5 |
HJMC
Hellman Jordan Management Company
Quincy,
Massachusetts
|
+$726K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.77M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.63M |
| 3 |
IMC Chicago
Chicago,
Illinois
|
-$857K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$838K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$765K |
LABU Hedge Fund Activity: Q2 2019 in Review
27 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2019, worth a combined $41.1M — down 12% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LABU positions and 2 closed out — a net gain of 4 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.56M. The largest seller was Morgan Stanley, cutting an estimated $5.77M.
- 27 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2019, up from 23 in Q1 2019.
- Funds reported $41.1M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2019, down 12% quarter-over-quarter.
- 6 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2019 and 2 closed out, a net change of +4 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2019 was Citadel Advisors, an estimated $4.56M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2019 was Morgan Stanley, an estimated $5.77M sold.
Based on aggregated 13F filings for Q2 2019.